Dialog Box

This research project will give women more time. Here's how.

For three decades, ovarian cancer treatment has seen almost no change. Currently, it involves a one-size-fits-all approach, ignoring all the different types of ovarian cancer and the different treatment each requires.

To make matters worse, ovarian cancer can often become resistant to treatment, leaving women with no other treatment options.

That's why we backed researchers at the Hudson Institute of Medical Research in their precision medicine project.


Precision medicine profiles a woman’s cancer and then matches it against over 2,000 different PBS-approved drugs to find which ones will be the most effective. Every woman is unique and precision medicine acknowledges that — providing individualised treatment that could be so much more effective than the current approach.

Already, the program has identified 16 drugs currently available on pharmacy shelves, that have never been used for ovarian cancer but are showing amazing promise in treating the disease. And there’s a chance that this treatment can ‘re-sensitise’ ovarian cancer cells to chemotherapy. 

We’ve tested over 2,000 drugs to rapidly understand and predict which will be the most effective treatment for each patient’s specific cancer type. From our initial trials, we’ve identified 16 drugs that show promise and have not previously been utilised in ovarian cancer treatment. In fact, 4 of the drugs were able to re-sensitise ovarian cancer cells to chemotherapy."

Dr Maree Bilandzic

OCRF-funded researcher, Hudson Institute of Medical Research


We are pleased that this research is continuing into its next phase of clinical trials on an expanded cohort of women.

This vital work wouldn't be possible without the support of the OCRF community backing innovative research. You can be a part of our community of research supporters by making a monthly donation to The Lab.

31 May 2021
Category: Research news